News - Mylan Laboratories, Financial


Popular Filters

Mylan 4th-qtr 2013 adjusted diluted EPS increases 20%, beating expectations


US generics major Mylan reported financial results for the fourth-quarter and full year 2013, showing…

FinancialGenericsMylan Laboratories

Teva denies claims its MS drug Copaxone profits set to slump

Teva denies claims its MS drug Copaxone profits set to slump


Israel’s Teva Pharmaceutical Industries, the world’s largest generic drugmaker, this morning strongly…

CopaxoneEuropeFinancialMylan LaboratoriesNeurologicalPatentsPharmaceuticalTeva Pharmaceutical Industries

Mylan's 2nd-qtr misses consensus on sales but beats on EPS


US generics drugmaker Mylan (Nasdaq: MYL) announced its financial results for the second quarter of 2013,…

FinancialGenericsMylan Laboratories

EU Commission fines Lundbeck and other Pharmas over "pay-for-delay" deals


In a much awaited decision following its investigations of patent settlements (or pay-for-delay deals)…

ActaviscitalopramEuropeFinancialGenericsLegalLundbeckMerck KGaAMylan LaboratoriesNeurologicalPatentsPharmaceuticalRanbaxy Laboratories

Mylan settles Provigil litigation with Teva


US generic major Mylan (Nasdaq: MYL) says that its subsidiary Mylan Pharmaceuticals has resolved all…

CephalonFinancialGenericsLegalMylan LaboratoriesNeurologicalNorth AmericaProvigilTeva Pharmaceutical Industries

News briefs: Genmab/GSK, Gilead and Mylan


Denmark's Genmab (OMX: GEN) yesterday received a milestone payment of 20 million Danish kroner ($3.4…

Anti-viralsBiotechnologycobicistatFinancialGenericsGenmabGilead SciencesGlaxoSmithKlineMylan LaboratoriesOncologyRegulationViramune

Mylan starts selling generic Lipitor in Europe; to buy back shares


US generic drug major Mylan's (Nasdaq: MYL) shares 2.2% to $21.55 in morning last Friday after the company…

atorvastatinCardio-vascularEuropeFinancialGenericsLipitorMarkets & MarketingMylan Laboratories

Merck & Co 1st-qtr earnings just beat expectations; wins Mylan patent dispute


US drug giant Merck & Co sales that global sales in the first-quarter of 2012 increased 1% to $11.7 billion,…

FinancialLegalMerck & CoMylan LaboratoriesNorth AmericaPatentsPharmaceuticalVytorinZetia

Valeant Pharma to acquire assets in Mexico; Mylan invests in Ireland


Acquisitive Canadian drugmaker Valeant Pharmaceuticals International (TSX: VRX) says it has signed an…

Atlantis PharmaEuropeFinancialGenericsMergers & AcquisitionsMylan LaboratoriesSouth AmericaValeant Pharmaceuticals

Mylan 4th-qtr profits beat expectations, but not sales


US generic drugs major Mylan (Nasdaq: MYL) yesterday posted financial results for the three months and…

FinancialGenericsMylan Laboratories

Mylan sees 2nd-qtr 2011 adjusted EPS rocket 41%


FinancialGenericsMylan Laboratories

Back to top